Navigation Links
New genomic marker for tuberculosis may help identify patients who will develop the disease
Date:8/29/2010

It may soon be possible to identify patients who will develop tuberculosis, as scientists have identified changes in the blood specific to the disease. These findings are from an international study published in the August 19 issue of Nature and conducted by doctors and researchers at Nationwide Children's Hospital using blood profiling techniques to understand infections.

Tuberculosis (TB) is caused by the bacterium Mycobacterium tuberculosis, which usually attacks the lungs and can be fatal if not treated properly. Although TB is no longer a leading cause of death in the United States, it remains an epidemic in much of the world. One third of the world's total population is infected with the microbes that cause TB; however, most people infected with M. tuberculosis remain asymptomatic with latent TB. People with latent TB have a 10 percent lifetime risk of developing active TB, but current tests can not identify which individuals will develop the disease.

"Tools to diagnose infections like TB, bronchiolitis and pneumonia have been developed and are actively used to classify patients as being infected with specific pathogens, but we are still unable to predict how each person is going to react to the infection," said one of the study's authors Octavio Ramilo, MD, chief of Infectious Diseases at Nationwide Children's Hospital. "It's difficult to predict patient outcomes, and this is a real problem."

To combat this problem, Dr. Ramilo and Asuncion Mejias, MD, investigators at the Center for Vaccines and Immunity in The Research Institute at Nationwide Children's Hospital, are using microarray technology to develop blood profiles in patients specific to infectious diseases.

"Each infectious agent, be it a virus or a bacterium, interacts with human immune cells in unique ways by triggering proteins on white blood cells," said Dr. Mejias. "We can identify patterns among the white blood cell's activated proteins and identify a unique 'signature' for each infectious agent."

Drs. Ramilo and Mejias' also faculty members at The Ohio State University College of Medicine research has shown that gene expression microarray technology can be used to help develop blood transcriptional signatures.

"This technology allows us to see the whole picture of infection using a single blood sample, which is a really powerful tool for the clinic," said Dr. Mejias.

It's this gene expression microarray technology that allowed an international group of investigators, of which Drs. Ramilo and Mejias are part of, to provide the first complete description of the blood transcriptional signature of TB.

The study examined and compared blood drawn from patients in London, England and Cape Town, South Africa who had active TB, latent TB or who did not have TB. The team developed genome-wide transcriptional profiles for each of the patients and discovered a distinct characteristic, or "signature," of the blood from patients with active TB. X-rays of patients with this signature were consistent with signs of active TB.

"The study shows for the first time that the transcriptional signature in blood correlates with extent of disease in active TB patients," said Dr. Ramilo. "It validates the idea that this transcriptional signature is an accurate marker of TB infection."

The team also found that a subset of latent TB patients had signatures similar to those in active TB patients.

"The signature of active TB, which was observed in 10 to 20 percent of latent TB patients, may identify those individuals who will develop disease, but longitudinal studies are needed to assess this," said Dr. Ramilo.

The transcriptional signature was diminished in active TB patients after two months and completely extinguished by 12 months after treatment.

"These findings suggest that the blood transcriptional signature of active TB patients could be used to monitor how well a patient's treatment is working," said Dr. Ramilo.

Dr. Mejias says that this study highlights the power that gene expression microarray technology could bring to the diagnosis and treatment of infectious diseases, as the blood transcriptional signatures are not limited to TB. Currently, the infectious disease investigators at Nationwide Children's Hospital are developing transcriptional signatures using blood samples obtained from children with broncholitis and pneumonia and plan to correlate findings with clinical outcomes, similar to the recent TB study.

"It seems that we are developing a tool that can not only diagnose infectious diseases, but also indicate severity and eventually predict which patients are at risk for developing advanced symptoms. These capabilities are desperately needed in order to improve how patients recover from infections," said Dr. Ramilo.


'/>"/>

Contact: Mary Ellen Peacock
MaryEllen.Peacock@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital
Source:Eurekalert

Related medicine news :

1. Large-scale genomic analysis of prostate cancer unveiled
2. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
3. Breast Cancer Patients Often Confused by Genomic Testing
4. Improvements needed in genomic test result discussions
5. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
6. SeqWright Advances Genomic Discovery With Isilon IQ
7. Researchers chart genomic map spanning over 2 dozen cancers
8. The cancer biomarker conundrum: Too many false discoveries
9. NIH launches effort to define markers of human immune responses
10. Biomarkers Could Spot Alzheimers Disease Early, Studies Suggest
11. A New Marker to Spot Aggressive Breast Cancers?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2016)... ... December 10, 2016 , ... The ... PATS recently joined forces with other healthcare organizations to promote diabetes education at ... in Harrisburg, featured a variety of speakers from around the Commonwealth of Pennsylvania. ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... and aural rehabilitation—provided by audiologists—to remain a critical part of public access to ... Drug Administration (FDA) announced this week that, starting immediately, it would ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... miniature, folded, pharmaceutical inserts and outserts. As a means of expanding capabilities ... addition will enable Flottman to individually code professional inserts (PIs) and patient package ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... Ball at The Pierre Hotel in New York, NY, on December 3rd, to ... dignitaries and physicians attended the annual event, which raised over $1 million - ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: